Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open‐label study
T Akizawa, T Otsuka, M Reusch… - … Apheresis and Dialysis, 2020 - Wiley Online Library
Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed to treat
anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24 …
anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24 …
Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study
S Fishbane, MA El-Shahawy… - Journal of the …, 2021 - journals.lww.com
Background Current anemia therapies for patients with non–dialysis-dependent CKD may
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
[HTML][HTML] Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial
YP Hou, XY Mao, C Wang, ZH Xu, ZH Bu, M Xu… - Journal of the Formosan …, 2022 - Elsevier
Background/purpose Roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase
inhibitor, promotes erythropoiesis and regulates iron metabolism. This study investigated the …
inhibitor, promotes erythropoiesis and regulates iron metabolism. This study investigated the …
A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis …
T Akizawa, Y Yamaguchi, T Otsuka, M Reusch - Nephron, 2020 - karger.com
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …
approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) …
Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and …
J Liu, A Zhang, JC Hayden, AS Bhagavathula… - Pharmacological …, 2020 - Elsevier
The effect of roxadustat (FG-4592) on individuals with chronic kidney diseases (CKD)
patients receiving or not receiving the dialysis was unclear. The aim of this study was to …
patients receiving or not receiving the dialysis was unclear. The aim of this study was to …
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
J Barratt, B Andric, A Tataradze… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …
[HTML][HTML] Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan
T Akizawa, M Iwasaki, Y Yamaguchi… - Journal of the …, 2020 - journals.lww.com
Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor
approved in China for dialysis-dependent CKD anemia. Methods This phase 3, 24-week …
approved in China for dialysis-dependent CKD anemia. Methods This phase 3, 24-week …
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney …
A Besarab, R Provenzano, J Hertel… - Nephrology Dialysis …, 2015 - academic.oup.com
Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …
[HTML][HTML] Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non–dialysis-dependent CKD: Pooled results of three randomized …
R Provenzano, L Szczech, R Leong… - Clinical journal of the …, 2021 - journals.lww.com
Results A total of 4277 patients with non–dialysis-dependent CKD were randomized
(roxadustat, n= 2391; placebo, n= 1886). Baseline characteristics were comparable between …
(roxadustat, n= 2391; placebo, n= 1886). Baseline characteristics were comparable between …